

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy Executive Summary

Heart Rhythm

5, 934-955

DOI: 10.1016/j.hrthm.2008.04.015

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Underuse of Overuse Research. Health Services Research, 2008, 43, 1923-1930.	2.0	26
3	Varying implantable cardioverter defibrillator referral patterns from implanting and non-implanting hospitals. Europace, 2009, 11, 1048-1051.	1.7	17
4	Preserved cardiac synchrony and function with single-site left ventricular epicardial pacing during mid-term follow-up in paediatric patients. Europace, 2009, 11, 1168-1176.	1.7	34
5	Implantable Cardioverter-Defibrillators. New England Journal of Medicine, 2009, 360, 937-938.	27.0	1
6	Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. European Heart Journal, 2009, 30, 2593-2598.	2.2	80
7	Extraction of pacemaker and implantable cardioverter defibrillator leads: a single-centre study of electrosurgical and laser extraction. Europace, 2009, 11, 1501-1504.	1.7	25
8	Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis. European Journal of Heart Failure, 2009, 11, 958-966.	7.1	76
9	Electrophysiological device therapy (implantable defibrillators) in older adults. Current Cardiovascular Risk Reports, 2009, 3, 347-354.	2.0	0
10	Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical characteristics of the initially enrolled cohort. American Heart Journal, 2009, 158, 364-370.e1.	2.7	105
11	Populations for CRT devices. Heart Rhythm, 2009, 6, 1373-1377.	0.7	3
12	Tratamiento de las arritmias hipoactivas. Marcapasos. Indicaciones y resultados. Medicine, 2009, 10, 2628-2633.	0.0	0
13	Protocolo de indicaciones de marcapasos. Medicine, 2009, 10, 2653-2656.	0.0	0
15	À qui proposer une resynchronisation? Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2009, 2009, 8-12.	0.0	0
16	Review of the ICD Registry's Third Year, Expansion to include Lead Data and Pediatric ICD Procedures, and Role for Measuring Performance. Heart Rhythm, 2009, 6, 1397-1401.	0.7	81
17	Risk of Arrhythmias in MYotonic Dystrophy: trial design of the RAMYD study. Journal of Cardiovascular Medicine, 2009, 10, 51-58.	1.5	37
18	Systematic Assessment of Basic Pacemaker Function. AACN Advanced Critical Care, 2010, 21, 322-328.	1.1	0
19	Low-dose spinal anesthesia in asymptomatic complete heart block without perioperative pacing. Journal of Anesthesia, 2010, 24, 660-661.	1.7	1
20	Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection. BMC Infectious Diseases, 2010, 10, 305.	2.9	37

#	ARTICLE	IF	CITATIONS
21	Predictors of Appropriate Implantable Cardioverter Defibrillator (ICD) Therapy in Primary Prevention Patients with Ischemic and Nonischemic Cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 320-329.	1.2	46
22	Termination of Electrocution-Induced Ventricular Fibrillation by an Implantable Cardioverter Defibrillator. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 510-512.	1.2	6
23	Perioperative Management of Anticoagulation during Device Implantation-The UK Perspective. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 389-393.	1.2	21
24	Response to Coceani: Has CRT Earned a Class I Recommendation?. Circulation: Heart Failure, 2010, 3, 559-560.	3.9	0
25	Risk Assessment for Sudden Cardiac Death in Dialysis Patients. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 553-559.	4.8	46
26	Systematic Assessment of Basic Pacemaker Function. AACN Advanced Critical Care, 2010, 21, 322-328.	1.1	3
27	Indications for Implantation of Cardiac Pacemakers. AACN Advanced Critical Care, 2010, 21, 227-232.	1.1	1
28	Dental care for patients with heart failure. Journal of the American Dental Association, 2010, 141, 845-853.	1.5	14
29	An Entirely Subcutaneous Implantable Cardioverter-Defibrillator. New England Journal of Medicine, 2010, 363, 36-44.	27.0	686
30	Role of implantable cardioverter defibrillators in non-ischaemic dilated cardiomyopathy. Postgraduate Medical Journal, 2010, 86, 116-122.	1.8	3
31	Lead removal in young patients in view of lifelong pacing. Europace, 2010, 12, 714-718.	1.7	29
32	EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace, 2010, 12, 1480-1489.	1.7	240
33	Relationship between cardiac autonomic function and sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillators. Europace, 2010, 12, 1725-1731.	1.7	23
34	Is the use of an additional pace/sense lead the optimal strategy for the avoidance of lead extraction in defibrillation lead failure? A single-centre experience. Europace, 2010, 12, 522-526.	1.7	8
35	Strategic choices to reduce implantable cardioverter-defibrillator-related morbidity. Nature Reviews Cardiology, 2010, 7, 376-383.	13.7	9
36	Safety and efficacy of a new magnetic resonance imaging-compatible pacing system: Early results of a prospective comparison with conventional dual-chamber implant outcomes. Heart Rhythm, 2010, 7, 750-754.	0.7	47
37	Is there new hope for sudden cardiac death prevention early after myocardial infarction?. Heart Rhythm, 2010, 7, 1598-1599.	0.7	3
38	An echocardiography-based technique for screening cardiac resynchronization therapy patients: DŒ©jŒvu all over again?. Heart Rhythm, 2010, 7, 1587-1588.	0.7	1

#	ARTICLE	IF	CITATIONS
39	Effect of Implantable Cardioverter-Defibrillator on Left Ventricular Ejection Fraction in Patients With Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 2010, 106, 1640-1645.	1.6	19
40	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Heart Rhythm, 2011, 8, 1308-1339.	0.7	995
42	Cardiac Resynchronization Therapy: What? Who? When? How?. American Journal of Medicine, 2011, 124, 813-815.	1.5	7
43	Evaluation of Resynchronization Therapy for Heart Failure in Patients With a QRS Duration Greater Than 120 ms (GREATER-EARTH) Trial: Rationale, Design, and Baseline Characteristics. Canadian Journal of Cardiology, 2011, 27, 779-786.	1.7	16
45	HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace, 2011, 13, 1077-1109.	1.7	699
46	Implantable-Cardioverter Defibrillator in Pediatric Population. , 0, , .		0
47	Dessincronia ventricular e aumento dos níveis de BNP na estimulação apical do ventrículo direito. Arquivos Brasileiros De Cardiologia, 2011, 97, 156-162.	0.8	5
48	Management of Acute Decompensated Heart Failure. , 2011, , 634-649.		0
49	Pacemaker, Defibrillator, and Lead Codes and Headers. , 2011, , 195-199.		1
50	Ethical issues on defibrillator deactivation in end-of-life patients. Journal of Cardiovascular Medicine, 2011, 12, 498-500.	1.5	2
51	Heart Transplantation for a Patient With Kearns-Sayre Syndrome and End-Stage Heart Failure. Congestive Heart Failure, 2011, 17, 101-103.	2.0	11
52	Electrophysiology and Adult Congenital Heart Disease: Advances and Options. Progress in Cardiovascular Diseases, 2011, 53, 281-292.	3.1	25
53	Trends in the Use and Outcomes of Implantable Cardioverter-Defibrillators in Patients Undergoing Dialysis in the United States. American Journal of Kidney Diseases, 2011, 58, 409-417.	1.9	110
54	Long-term Follow-up of Prophylactic Implantable Cardioverter-Defibrillator-Only Therapy: Comparison of Ischemic and Nonischemic Heart Disease. Clinical Cardiology, 2011, 34, 761-767.	1.8	17
55	Health care utilisation after defibrillator implantation for primary prevention according to the guidelines in 2 Dutch academic medical centres. Netherlands Heart Journal, 2011, 19, 405-411.	0.8	6
56	Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clinical Research in Cardiology, 2011, 100, 737-744.	3.3	91
57	Right ventricular dysfunction is a predictor of non-response and clinical outcome following cardiac resynchronization therapy. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 68.	3.3	46
58	Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. Cmaj, 2011, 183, 421-429.	2.0	112

#	ARTICLE	IF	CITATIONS
59	The role of implantable cardioverter defibrillators in high-risk CABG patients identified early post-cardiac surgery. <i>Europace</i> , 2011, 13, 70-76.	1.7	7
60	THE HILBERT MARGINAL SPECTRUM ANALYSIS AND FEATURE EXTRACTION OF SHORT-TERM HEART RATE SIGNAL OF SPONTANEOUS VENTRICULAR TACHYARRHYTHMIA. <i>Biomedical Engineering - Applications, Basis and Communications</i> , 2011, 23, 467-478.	0.6	2
61	Guideline-driven telemonitoring and follow-up of cardiovascular implantable electronic devices using IEEE 11073, HL7 & IHE profiles. , 2011, 2011, 3192-6.		4
62	Left Ventricular Versus Simultaneous Biventricular Pacing in Patients With Heart Failure and a QRS Complex ≥ 120 Milliseconds. <i>Circulation</i> , 2011, 124, 2874-2881.	1.6	129
63	Abnormal Response of Superior Sinoatrial Node to Sympathetic Stimulation Is a Characteristic Finding in Patients With Atrial Fibrillation and Symptomatic Bradycardia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011, 4, 799-807.	4.8	31
64	Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers. <i>Europace</i> , 2011, 13, 1419-1427.	1.7	24
65	Impact of left ventricular ejection fraction on occurrence of ventricular events in defibrillator patients with coronary artery disease. <i>Europace</i> , 2011, 13, 1562-1567.	1.7	4
66	Rationale and design for programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock (PROVIDE) study. <i>Europace</i> , 2011, 13, 1648-1652.	1.7	12
67	The bisferiens pulse. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2011, 72, M189-M191.	0.5	3
68	Comparison of a Novel, Single-Lead Atrial Sensing System With a Dual-Chamber Implantable Cardioverter-Defibrillator System in Patients Without Antibradycardia Pacing Indications. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011, 4, 56-63.	4.8	47
69	The Hilbert marginal spectrum analysis of short-term heart rate signal prior to spontaneous onset of ventricular tachyarrhythmia. , 2011, , .		1
70	The Extent of Left Ventricular Scar Quantified by Late Gadolinium Enhancement MRI Is Associated With Spontaneous Ventricular Arrhythmias in Patients With Coronary Artery Disease and Implantable Cardioverter-Defibrillators. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011, 4, 324-330.	4.8	117
71	Risk Factor and Prediction Modeling for Sudden Cardiac Death in Women With Coronary Artery Disease. <i>Archives of Internal Medicine</i> , 2011, 171, 1703.	3.8	36
72	Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy-Dysplasia. , 2012, , 625-639.		0
73	Lost in Translation. <i>Circulation: Heart Failure</i> , 2012, 5, 660-666.	3.9	13
74	Arrhythmias in cardiac sarcoidosis. <i>Current Opinion in Cardiology</i> , 2012, 27, 181-189.	1.8	44
75	Do patients at high risk of nonsudden cardiac death benefit from prophylactic ICD therapy?. <i>Current Opinion in Cardiology</i> , 2012, 27, 1-7.	1.8	4
76	Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2012, 126, 2402-2407.	1.6	66

#	ARTICLE	IF	CITATIONS
77	Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace, 2012, 14, 1490-1497.	1.7	78
78	Atrial fibrillation in cardiac resynchronization therapy patients: should we ablate the atrioventricular node?. Expert Review of Cardiovascular Therapy, 2012, 10, 843-845.	1.5	1
79	The Transcatheter Valve Revolution. Circulation, 2012, 126, 674-676.	1.6	3
80	Ventricular Arrhythmias in Hypertrophic Cardiomyopathy. , 2012, , 618-624.		1
81	Left ventricular lead position for cardiac resynchronization: a comprehensive cinegraphic, echocardiographic, clinical, and survival analysis. Europace, 2012, 14, 1139-1147.	1.7	54
82	Ventricular tachycardia or ventricular fibrillation occurs less often in patients with left bundle branch block and combined resynchronization and defibrillators than in patients with narrow QRS and conventional defibrillators. Europace, 2012, 14, 224-229.	1.7	10
83	Challenges in cardiac resynchronization therapy-defibrillator upgrade in a patient with right pneumonectomy. Europace, 2012, 14, 1497-1497.	1.7	0
84	Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers. Yearbook of Cardiology, 2012, 2012, 299-303.	0.0	0
85	Predictors of Super-Response to Cardiac Resynchronization Therapy and Associated Improvement in Clinical Outcome. Journal of the American College of Cardiology, 2012, 59, 2366-2373.	2.8	252
86	Antibiotics and Antiseptics to Prevent Infection in Cardiac Rhythm Management Device Implantation Surgery. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 1348-1360.	1.2	49
87	Intraventricular Conduction Abnormalities. , 2012, , 194-211.		2
88	Ventricular Arrhythmias in Inherited Channelopathies. , 2012, , 645-684.		1
89	CRT or CRT-D devices? The case for "high energy"™ devices. Heart Failure Reviews, 2012, 17, 777-779.	3.9	0
90	Subcutaneous chronic implantable defibrillation systems in humans. Journal of Interventional Cardiac Electrophysiology, 2012, 34, 325-332.	1.3	19
91	A case of Prinzmetal angina diagnosed by Holter monitoring who survived a sudden cardiac death: Case report. Journal of Cardiology Cases, 2012, 6, e88-e90.	0.5	1
92	Guidelines for implantation of primary prevention defibrillators: Who is listening?. Heart Rhythm, 2012, 9, 882-883.	0.7	0
93	Rem sleep brady-arrhythmias: An indication to pacemaker implantation?. Sleep Medicine, 2012, 13, 759-762.	1.6	14
94	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart		

#	ARTICLE	IF	CITATIONS
95	Arrhythmias in the Coronary Care Unit. <i>Journal of Intensive Care Medicine</i> , 2012, 27, 267-289.	2.8	4
96	Sinus nodal response to adenosine relates to the severity of sinus node dysfunction. <i>Europace</i> , 2012, 14, 859-864.	1.7	12
97	Cardiac Implantable Electronic Device Therapy for Bradyarrhythmias and Tachyarrhythmias. <i>Heart Lung and Circulation</i> , 2012, 21, 328-337.	0.4	2
98	Prophylactic cardioverter defibrillator utilization in the "real world": A conundrum. <i>International Journal of Cardiology</i> , 2012, 156, 123-124.	1.7	3
99	Arrhythmia management: Advances and new perspectives in pharmacotherapy in congenital heart disease. <i>Progress in Pediatric Cardiology</i> , 2012, 34, 69-73.	0.4	1
100	Concealed Long QT Syndrome and Intractable Partial Epilepsy: A Case Report. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1128-1131.	3.0	14
101	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. <i>Heart Rhythm</i> , 2012, 9, 1524-1576.	0.7	300
103	Perioperative Management of Patients with Bradycardia. <i>The Journal of Japan Society for Clinical Anesthesia</i> , 2012, 32, 468-473.	0.0	0
104	Rates of Upgrade of ICD Recipients to CRT in Clinical Practice and the Potential Impact of the More Liberal Use of CRT at Initial Implant. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 73-80.	1.2	22
105	Method of Pacing Does Not Affect the Recurrence of Syncope in Carotid Sinus Syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 827-833.	1.2	16
106	Extraordinarily Favorable Left Ventricular Reverse Remodeling through Long-Term Cardiac Resynchronization: Super-Response to Cardiac Resynchronization. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 870-876.	1.2	11
107	Value of Dynamic Substrate Mapping to Identify the Critical Diastolic Pathway in Postoperative Ventricular Reentrant Tachycardias After Surgical Repair of Tetralogy of Fallot. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 930-937.	1.7	13
108	Development of an Entirely Subcutaneous Implantable Cardioverter-Defibrillator. <i>Progress in Cardiovascular Diseases</i> , 2012, 54, 493-497.	3.1	9
109	Perioperative Assessment of Patients With Cardiac Implantable Electronic Devices. <i>Mount Sinai Journal of Medicine</i> , 2012, 79, 25-33.	1.9	7
110	Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. <i>Heart Rhythm</i> , 2013, 10, 214-218.	0.7	15
111	The pathway to physician reimbursement for cardiac implantable electronic devices (CIEDs): a history and brief synopsis. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 36, 137-144.	1.3	3
112	A novel mitochondrial DNA deletion in a patient with Kearns-Sayre syndrome: a late-onset of the fatal cardiac conduction deficit and cardiomyopathy accompanying long-term rGH treatment. <i>BMC Pediatrics</i> , 2013, 13, 27.	1.7	19
113	Consideration of patient age and life expectancy in implantable cardioverter-defibrillator referral. <i>American Heart Journal</i> , 2013, 166, 164-170.e5.	2.7	6

#	ARTICLE	IF	CITATIONS
114	Implantable Cardiac Devices Technology. , 2013, , .		7
115	Multi-contrast late enhancement CMR determined gray zone and papillary muscle involvement predict appropriate ICD therapy in patients with ischemic heart disease. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 57.	3.3	21
116	Impact of shock energy and ventricular rhythm on the success of first shock therapy: The ALTITUDE first shock study. Heart Rhythm, 2013, 10, 702-708.	0.7	15
117	Incidence of Appropriate Shock in Implantable Cardioverter-Defibrillator Patients With Improved Ejection Fraction. Journal of Cardiac Failure, 2013, 19, 426-430.	1.7	59
118	Advances in Cardiac SPECT and PET Imaging: Overcoming the Challenges to Reduce Radiation Exposure and Improve Accuracy. Canadian Journal of Cardiology, 2013, 29, 275-284.	1.7	19
119	Stroke or Transient Ischemic Attack in Patients With Transvenous Pacemaker or Defibrillator and Echocardiographically Detected Patent Foramen Ovale. Circulation, 2013, 128, 1433-1441.	1.6	87
120	Spanish Implantable Cardioverter-defibrillator Registry. Ninth Official Report of the Spanish Society of Cardiology Electrophysiology and Arrhythmias Section (2012). Revista Espanola De Cardiologia (English Ed), 2013, 66, 881-893.	0.6	25
121	Relationship between Left Atrial Function and Size and Level of Left Ventricular Dyssynchrony in Heart Failure Patients. Echocardiography, 2013, 30, 772-777.	0.9	9
122	Sinus node disease in subjects with type 1 ECG pattern of Brugada syndrome. Journal of Cardiology, 2013, 61, 227-231.	1.9	17
123	Socio-economic effects and cost saving potential of remote patient monitoring (SAVE-HM trial). International Journal of Cardiology, 2013, 169, 402-407.	1.7	61
124	Syncope in the Older Person. Cardiac Electrophysiology Clinics, 2013, 5, 457-467.	1.7	1
125	Bloqueo auriculoventricular completo en contexto de periparada. FMC Formacion Medica Continuada En Atencion Primaria, 2013, 20, 238-239.	0.0	0
126	Tachycardia. Disease-a-Month, 2013, 59, 74-82.	1.1	3
127	Atrial Fibrillation in Heart Failure in the Older Population. Heart Failure Clinics, 2013, 9, 451-459.	2.1	6
128	Delayed intrinsicoid deflection onset in surface ECG lateral leads predicts left ventricular reverse remodeling after cardiac resynchronization therapy. Heart Rhythm, 2013, 10, 979-987.	0.7	27
129	Cardiac MRI scar patterns differ by sex in an implantable cardioverter-defibrillator and cardiac resynchronization therapy cohort. Heart Rhythm, 2013, 10, 659-665.	0.7	22
130	Cardiac resynchronisation and defibrillation therapy: Advances and challenges. Journal of Arrhythmia, 2013, 29, 143-143.	1.2	0
131	Telecardiology: Past, Present and Future. Revista Espanola De Cardiologia (English Ed), 2013, 66, 212-218.	0.6	8

#	ARTICLE	IF	CITATIONS
132	Causes and prevention of sudden cardiac death in the elderly. <i>Nature Reviews Cardiology</i> , 2013, 10, 135-142.	13.7	39
133	Anatomy of the Coronary Sinus and Epicardial Coronary Venous System in 620 Hearts: An Electrophysiology Perspective. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 1-6.	1.7	58
134	Indications for Implantable System Treatment. , 2013, , 33-41.		0
135	Impact of the Advia MRI pacing system on the diagnostic quality of cardiac MR images and contraction patterns of cardiac muscle during scans: Advia MRI randomized clinical multicenter study results. <i>Heart Rhythm</i> , 2013, 10, 864-872.	0.7	42
136	Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. <i>Europace</i> , 2013, 15, 1389-1406.	1.7	494
137	Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block. <i>Heart</i> , 2013, 99, 334-338.	2.9	38
139	Device measured physical activity as a predictor of reverse remodeling and clinical outcome. <i>European Heart Journal</i> , 2013, 34, P3169-P3169.	2.2	0
140	Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study. <i>European Heart Journal Cardiovascular Imaging</i> , 2013, 14, 387-395.	1.2	124
141	Remote monitoring costs, benefits, and reimbursement: a European perspective. <i>Europace</i> , 2013, 15, i59-i64.	1.7	25
142	Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 305, H1181-H1188.	3.2	20
143	Role of Implantable Cardioverter-Defibrillators in Primary and Secondary Prevention of Sudden Cardiac Death. , 2013, , 396-407.		0
144	Device Infections. <i>Circulation</i> , 2013, 128, 1031-1038.	1.6	35
145	Documented consent process for implantable cardioverter-defibrillators and implications for end-of-life care in older adults. <i>Journal of Medical Ethics</i> , 2013, 39, 94-97.	1.8	15
146	Clinical Characteristics, Mortality, Cardiac Hospitalization, and Ventricular Arrhythmias in Patients Undergoing CRTâ€”Implantation: Results of the ACTIONâ€”HF Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 173-181.	1.7	9
147	Complete Heart Block Following Valve Surgery: Violation of the â€œPrimum Non Nocereâ€”Maxim or a Minor Secondary Event?. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 1388-1390.	1.7	0
148	Genotypeâ€”Specific Risk Stratification and Management of Patients with Long QT Syndrome. <i>Annals of Noninvasive Electrocardiology</i> , 2013, 18, 499-509.	1.1	37
149	Sonication of Explanted Cardiac Implants Improves Microbial Detection in Cardiac Device Infections. <i>Journal of Clinical Microbiology</i> , 2013, 51, 496-502.	3.9	38
150	Implantable Cardioverter-Defibrillators in Patients With COPD. <i>Chest</i> , 2013, 144, 778-783.	0.8	11

#	ARTICLE	IF	CITATIONS
151	Is Conventional Cardiac Pacing Harmful in Patients with Normal Ventricular Function?. Arquivos Brasileiros De Cardiologia, 2013, 101, 545-53.	0.8	4
152	Pauses in the Electrocardiogram of a Woman with Chest Pain and Lightheadedness. Baylor University Medical Center Proceedings, 2013, 26, 275-276.	0.5	0
154	Development and evaluation of the EOL-ICDQ as a measure of experiences, attitudes and knowledge in end-of-life in patients living with an implantable cardioverter defibrillator. European Journal of Cardiovascular Nursing, 2014, 13, 142-151.	0.9	20
155	Time Dependence of Risks and Benefits in Pediatric Primary Prevention Implantable Cardioverter-Defibrillator Therapy. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1057-1063.	4.8	36
156	Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure. BMJ, The, 2014, 348, g2866-g2866.	6.0	30
158	Cardioversor desfibrilhador implantável subcutâneo “experiência de um centro. Revista Portuguesa De Cardiologia, 2014, 33, 511-517.	0.5	4
159	Long-Term Arrhythmia-Free Survival in Patients With Severe Left Ventricular Dysfunction and No Inducible Ventricular Tachycardia After Myocardial Infarction. Circulation, 2014, 129, 848-854.	1.6	58
160	Implantable Defibrillators With Enhanced Detection Algorithms: Detection Performance and Safety Results from the PainFree SST Study. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 1198-1209.	1.2	19
161	Programming Implantable Cardioverter-Defibrillators in Patients with Primary Prevention Indication to Prolong Time to First Shock: Results from the PROVIDE Study. Journal of Cardiovascular Electrophysiology, 2014, 25, 52-59.	1.7	114
162	The Use of Signal Analyses of Ventricular Tachycardia Electrograms to Predict the Response of Antitachycardia Pacing in Patients with Implantable Cardioverter-Defibrillators. Journal of Cardiovascular Electrophysiology, 2014, 25, 411-417.	1.7	8
163	Evaluation and Management of Heart Rhythm Disturbances Due to Cardiac Sarcoidosis. Heart Lung and Circulation, 2014, 23, 1100-1109.	0.4	9
164	Pacing and Implantable Cardioverter Defibrillator Lead Perforation As Assessed by Multiplanar Reformatted ECG-Gated Cardiac Computed Tomography and Clinical Correlates. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 537-545.	1.2	26
165	Implantable Cardioverter Defibrillator System with Floating Atrial Sensing Dipole: A Single-Center Experience. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 1265-1273.	1.2	19
166	Sleep-disordered breathing increases the risk of arrhythmias. Journal of Cardiovascular Medicine, 2014, 15, 411-416.	1.5	13
167	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. Heart Rhythm, 2014, 11, 1270-1303.	0.7	16
169	Usefulness of Hyponatremia as a Predictor for Adverse Events in Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. American Journal of Cardiology, 2014, 114, 83-87.	1.6	7
170	Ventricular Tachycardia in Patients With Dilated Cardiomyopathy. , 2014, , 859-871.		0
171	Spouses’ reflections on Implantable Cardioverter Defibrillator treatment with focus on the future and the end-of-life: a qualitative content analysis. Journal of Advanced Nursing, 2014, 70, 1758-1769.	3.3	14

#	ARTICLE	IF	CITATIONS
172	Should Catheter Ablation be the Preferred Approach for Treatment of Atrial Fibrillation Related Symptomatic Sinus Node Dysfunction?. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 401-402.	1.2	2
173	Subcutaneous implantable cardioverter-defibrillator: Initial experience. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 511-517.	0.2	2
174	Treatment of dilated cardiomyopathy. British Journal of Cardiac Nursing, 2014, 9, 297-302.	0.1	0
175	Ethical Challenges of Deactivation of Cardiac Devices in Advanced Heart Failure. Current Heart Failure Reports, 2014, 11, 119-125.	3.3	16
177	Correlation between vectorcardiographic measures and cardiac magnetic resonance imaging of the left ventricle in an implantable cardioverter defibrillator population. Journal of Electrocardiology, 2014, 47, 52-58.	0.9	12
178	HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. Heart Rhythm, 2014, 11, 1304-1323.	0.7	1,077
179	Device-Measured Physical Activity Versus Six-Minute Walk Test as a Predictor of Reverse Remodeling and Outcome After Cardiac Resynchronization Therapy for Heart Failure. American Journal of Cardiology, 2014, 113, 1523-1528.	1.6	34
180	Utilization rates of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: A 2012 calculation for a midwestern health referral region. Heart Rhythm, 2014, 11, 849-855.	0.7	19
182	Correlation of the New York Heart Association Classification and the 6â€¢Minute Walk Distance: A Systematic Review. Clinical Cardiology, 2015, 38, 621-628.	1.8	76
183	Implantable defibrillators versus medical therapy for cardiac channelopathies. The Cochrane Library, 2015, , CD011168.	2.8	9
184	Modifying Ventricular Fibrillation by Targeted Rotor Substrate Ablation: Proofâ€¢ofâ€¢Concept from Experimental Studies to Clinical VF. Journal of Cardiovascular Electrophysiology, 2015, 26, 1117-1126.	1.7	35
185	Cardiac Resynchronization Therapy in 2015: Lessons Learned. Cardiovascular Innovations and Applications, 2015, 1, .	0.3	0
186	Assessing Health Literacy in Urban Patients With Implantable Cardioverter Defibrillators and Pacemakers. Journal of Cardiovascular Nursing, 2015, 30, 428-434.	1.1	11
187	Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). Journal of Cardiac Failure, 2015, 21, 479-488.	1.7	69
188	Incidence of and risk factors for infectious complications in patients with cardiac device implantation. International Journal of Infectious Diseases, 2015, 36, 9-14.	3.3	23
189	Analysis of speed, curvature, planarity and frequency characteristics of heart vector movement to evaluate the electrophysiological substrate associated with ventricular tachycardia. Computers in Biology and Medicine, 2015, 65, 150-160.	7.0	14
190	A Comparison of Right Ventricular Non-apical Defibrillator Lead Position with Traditional Right Ventricular Apical Position: A Single Centre Experience. Heart Lung and Circulation, 2015, 24, 179-184.	0.4	1
191	Effects of Tricuspid Valve Regurgitation on Outcome in Patients With Cardiac Resynchronization Therapy. American Journal of Cardiology, 2015, 115, 783-789.	1.6	20

#	ARTICLE	IF	CITATIONS
192	Advanced Imaging of Cardiac Sarcoidosis. Current Cardiology Reports, 2015, 17, 17.	2.9	14
193	Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. European Heart Journal, 2015, 36, 1660-1668.	2.2	329
194	Syncope in the Older Person. Cardiology Clinics, 2015, 33, 411-421.	2.2	12
195	Athletes with Implantable Cardioverter Defibrillators. Clinics in Sports Medicine, 2015, 34, 473-487.	1.8	11
196	A Cold Taken to Heart. Circulation, 2015, 131, 1703-1711.	1.6	0
197	Sudden Cardiac Death. Current Problems in Cardiology, 2015, 40, 133-200.	2.4	116
198	Medical Treatment of Heart Failure and Coronary Heart Disease. Cardiovascular Medicine, 2015, , 533-560.	0.0	0
199	Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: From the Israeli ICD Registry. Heart Rhythm, 2015, 12, 2426-2433.	0.7	82
200	Clinical Cardiac Electrophysiology in the Young. , 2015, , .		0
201	Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. Cardiac Electrophysiology Clinics, 2015, 7, 695-707.	1.7	1
202	Implantable cardioverter-defibrillator and wait-list outcomes in pediatric patients awaiting heart transplantation. Heart Rhythm, 2015, 12, 2443-2448.	0.7	13
203	Registro Español de Desfibrilador Automático Implantable. XI Informe Oficial de la Sección de Electrofisiología y Arritmias de la Sociedad Española de Cardiología (2014). Revista Espanola De Cardiologia, 2015, 68, 996-1007.	1.2	16
204	Spanish Implantable Cardioverter-defibrillator Registry. Eleventh Official Report of the Spanish Society of Cardiology Electrophysiology and Arrhythmias Section (2014). Revista Espanola De Cardiologia (English Ed), 2015, 68, 996-1007.	0.6	0
205	Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Failure Reviews, 2015, 20, 163-178.	3.9	178
207	Patient perceptions of implantable cardioverter-defibrillator deactivation discussions: A qualitative study. SAGE Open Medicine, 2016, 4, 205031211664269.	1.8	9
209	Ventricular fibrillation: triggers, mechanisms and therapies. Future Cardiology, 2016, 12, 373-390.	1.2	17
210	Arrhythmogenic Right Ventricular Cardiomyopathy: Risk Stratification and Indications for Defibrillator Therapy. Current Cardiology Reports, 2016, 18, 57.	2.9	20
211	His bundle pacing: Initial experience and lessons learned. Journal of Electrocardiology, 2016, 49, 658-663.	0.9	4

#	ARTICLE	IF	CITATIONS
212	Evaluación comparativa de cuatro puntuaciones de riesgo para predecir la mortalidad de pacientes con desfibrilador automático implantable en prevención primaria. Revista Espanola De Cardiologia, 2016, 69, 1033-1041.	1.2	2
213	Cardiac Device Related Endocarditis. , 2016, , 187-205.		1
214	Echocardiographic Predictors of Sudden Cardiac Death. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	31
215	Long-term Intrinsic Rhythm Evaluation in Dogs with Atrioventricular Block. Journal of Veterinary Internal Medicine, 2016, 30, 58-62.	1.6	16
216	Risk stratification for sudden cardiac death in North America – current perspectives. Journal of Electrocardiology, 2016, 49, 817-823.	0.9	15
217	Comparative Evaluation of Four Risk Scores for Predicting Mortality in Patients With Implantable Cardioverter-defibrillator for Primary Prevention. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1033-1041.	0.6	1
219	Spanish Implantable Cardioverter-defibrillator Registry. Twelfth Official Report of the Spanish Society of Cardiology Electrophysiology and Arrhythmias Section (2015). Revista Espanola De Cardiologia (English Ed), 2016, 69, 1168-1179.	0.6	2
220	Interplay between right ventricular mechanical dyssynchrony and cardiac resynchronization therapy in patients with nonischemic dilated cardiomyopathy. Nuclear Medicine Communications, 2016, 37, 1016-1023.	1.1	3
221	Delayed intrinsicoid deflection of the QRS complex is associated with sudden cardiac arrest. Heart Rhythm, 2016, 13, 927-932.	0.7	19
222	Arrhythmia diagnosis and management throughout life in congenital heart disease. Expert Review of Cardiovascular Therapy, 2016, 14, 301-320.	1.5	7
223	The Authors Reply:. JACC: Cardiovascular Imaging, 2016, 9, 327-328.	5.3	0
224	Complications arising from cardiac implantable electrophysiological devices: review of epidemiology, pathogenesis and prevention for the clinician. Postgraduate Medicine, 2016, 128, 223-230.	2.0	17
225	Insertion and Management of Temporary Pacemakers. Seminars in Cardiothoracic and Vascular Anesthesia, 2016, 20, 52-62.	1.0	23
226	The Romhilt-Estes electrocardiographic score predicts sudden cardiac arrest independent of left ventricular mass and ejection fraction. Annals of Noninvasive Electrocardiology, 2017, 22, .	1.1	8
227	Cost Analysis of Patients Referred for Inherited Heart Rhythm Disorder Evaluation. Canadian Journal of Cardiology, 2017, 33, 814-821.	1.7	3
228	Endocardial Device Leads in Patients with Patent Foramen Ovale: Echocardiographic Correlates of Stroke/TIA and Mortality. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 310-322.	1.2	2
229	Heart Rhythm Society: expert consensus statements – part 1. Clinical Cardiology, 2017, 40, 177-185.	1.8	1
230	CMR in Phenotyping the Arrhythmic Substrate. Current Cardiovascular Imaging Reports, 2017, 10, 1.	0.6	0

#	ARTICLE	IF	CITATIONS
231	Impaired left atrial function predicts inappropriate shocks in primary prevention implantable cardioverter-defibrillator candidates. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 796-805.	1.7	10
232	Cardiovascular Implantable Electronic Devices. <i>Hospital Medicine Clinics</i> , 2017, 6, 1-15.	0.2	1
233	Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. <i>Heart Failure Clinics</i> , 2017, 13, 139-151.	2.1	0
234	The subcutaneous defibrillator: Modest step or quantum leap?. <i>Heart Rhythm</i> , 2017, 14, 1464-1465.	0.7	1
235	Recent Advances and Clinical Applications of PET Cardiac Autonomic Nervous System Imaging. <i>Current Cardiology Reports</i> , 2017, 19, 33.	2.9	33
236	Ventricular Arrhythmias in Adult Congenital Heart Disease. <i>Cardiac Electrophysiology Clinics</i> , 2017, 9, 213-223.	1.7	9
237	Cardiac implantable electronic device infections: Who is at greatest risk?. <i>Heart Rhythm</i> , 2017, 14, 839-845.	0.7	70
238	Predictors and long-term outcome of super-responders to cardiac resynchronization therapy. <i>Clinical Cardiology</i> , 2017, 40, 292-299.	1.8	25
239	Heart failure with reduced ejection fraction. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17058.	30.5	136
240	A Blueprint for the Post Discharge Clinic Visit after an Admission for Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2017, 60, 237-248.	3.1	11
241	Syncope and the risk of sudden cardiac death: Evaluation, management, and prevention. <i>Journal of Arrhythmia</i> , 2017, 33, 533-544.	1.2	46
243	Role of cardiac pacing in congenital complete heart block. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 853-861.	1.5	25
244	Consensus Document of the Italian Association of Hospital Cardiologists (ANMCO), Italian Society of Pediatric Cardiology (SICP), and Italian Society of Gynaecologists and Obstetrics (SIGO): pregnancy and congenital heart diseases. <i>European Heart Journal Supplements</i> , 2017, 19, D256-D292.	0.1	13
245	How to Evaluate for and Manage Inflammatory and Infiltrative Cardiomyopathies that Require Ventricular Tachycardia Ablation. <i>Current Cardiovascular Risk Reports</i> , 2017, 11, 1.	2.0	0
246	Spanish Implantable Cardioverter-defibrillator Registry. 13th Official Report of the Spanish Society of Cardiology Electrophysiology and Arrhythmias Section (2016). <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 960-970.	0.6	2
247	Cardiac Resynchronization Therapy in Older Adults with Heart Failure. <i>Heart Failure Clinics</i> , 2017, 13, 581-587.	2.1	7
248	Reasons for and predictors of acute hospitalization versus elective outpatient implantable cardioverter-defibrillator implantation and subsequent differential clinical outcomes. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 85-93.	1.3	1
249	Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients—a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2018, 23, 181-190.	3.9	15

#	ARTICLE	IF	CITATIONS
250	Electrophysiologic features of protected channels in late postinfarction patients with and without spontaneous ventricular tachycardia. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 13-24.	1.3	9
251	Cause for Pause: Obstructive Sleep Apnea. American Journal of Medicine, 2018, 131, 141-143.	1.5	0
252	Arrhythmias in the Pediatric Population. , 2018, , 1032-1044.		3
253	Cardiac resynchronization therapy is associated with improvement in clinical outcomes in Indian heart failure patients: Results of a large, long-term observational study. Indian Heart Journal, 2018, 70, S377-S383.	0.5	4
254	A Case of Complete Heart Block With Diagnostic Challenge and Therapeutic Dilemma. Journal of Investigative Medicine High Impact Case Reports, 2018, 6, 232470961878811.	0.6	3
255	Impact of transvenous cardiac implantable electronic devices in chronic hemodialysis patients: a single-center, observational comparative study. BMC Nephrology, 2018, 19, 281.	1.8	4
257	Assessment of Implantable Cardioverter-Defibrillator Used in Heart Failure with Reduced Ejection Fraction as Primary Prevention in an Underserved Population. Journal of General Internal Medicine, 2018, 33, 1854-1856.	2.6	0
258	FDA perspective on assessing the clinical benefit of cardiac resynchronization and implantable cardioverter-defibrillator devices. Journal of Electrocardiology, 2018, 51, S22-S24.	0.9	0
259	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace, 2019, 21, 7-8.	1.7	72
260	Long term performance and safety of His bundle pacing: A multicenter experience. Journal of Cardiovascular Electrophysiology, 2019, 30, 1594-1601.	1.7	107
261	Heart Failure Duration Combined with Left Atrial Dimension Predicts Super-Response and Long-Term Prognosis in Patients with Cardiac Resynchronization Therapy Implantation. BioMed Research International, 2019, 2019, 1-8.	1.9	0
262	Comparison of outcomes in infected cardiovascular implantable electronic devices between complete, partial, and failed lead removal: an ESC-EHRA-EORP ELECTRa (European Lead Extraction ConTrolled) registry. Europace, 2019, 21, 1876-1889.	1.7	10
263	JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosisâ€• Digest Version â€•. Circulation Journal, 2019, 83, 2329-2388.	1.6	237
265	Subcutaneous ICD: Current standards and future perspective. IJC Heart and Vasculature, 2019, 24, 100409.	1.1	26
266	His-Optimized Cardiac Resynchronization Therapy to Maximize Electrical Resynchronization. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006934.	4.8	133
267	Repaired Complete Atrioventricular Septal Defect Patient With Late Bradyarrhythmia. , 2019, , 149-156.		0
268	Risk Factors Associated With Atrioventricular Block. JAMA Network Open, 2019, 2, e194176.	5.9	40
269	Subcutaneous nerve stimulation for rate control in ambulatory dogs with persistent atrial fibrillation. Heart Rhythm, 2019, 16, 1383-1391.	0.7	11

#	ARTICLE	IF	CITATIONS
270	Efficacy of the current of injury in envisaging the dislodgement of leads implanted in the right atrial septum or the right ventricular septum. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 603-609.	1.2	4
271	Neonates and infants requiring life-long cardiac pacing: How reliable are epicardial leads through childhood?. <i>International Journal of Cardiology</i> , 2019, 297, 43-48.	1.7	8
272	Leadless Permanent Pacing: A Single Centre Australian Experience. <i>Heart Lung and Circulation</i> , 2019, 28, 1677-1682.	0.4	5
273	Leadless Cardiac Pacemaker (LCP) without Diagnostic Relevant Artifacts in DualSource and DualEnergy-CT Examinations in First- to Third-Generation DSCT Scanner. <i>Academic Radiology</i> , 2019, 26, 1071-1076.	2.5	1
274	Pericardial complications and postcardiac injury syndrome after cardiovascular implantable electronic device placement. <i>Herz</i> , 2020, 45, 58-66.	1.1	1
275	Management of Arrhythmias and Device Therapy in Heart Failure. , 2020, , 549-567.		0
276	Wearable cardioverter-defibrillators in pediatric cardiomyopathy: A cost-utility analysis. <i>Heart Rhythm</i> , 2020, 17, 287-293.	0.7	4
277	Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: Improve SCA clinical trial. <i>Heart Rhythm</i> , 2020, 17, 468-475.	0.7	22
280	Cost utility of wearable cardioverter-defibrillators in children with dilated cardiomyopathy during medical optimization: Is it worth the wait?. <i>Heart Rhythm</i> , 2020, 17, 294-295.	0.7	0
281	Comparison of Left Bundle Branch and His Bundle Pacing in Bradycardia Patients. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1291-1299.	3.2	64
282	Social cognitive intervention following an initial implantable cardioverter defibrillator: Better treatment response for secondary versus primary prevention. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 974-982.	1.2	3
283	Predictors of short-term mortality in patients undergoing a successful uncomplicated extraction procedure. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1155-1162.	1.7	6
284	Approach to a Child with Congestive Heart Failure. <i>Indian Journal of Pediatrics</i> , 2020, 87, 312-320.	0.8	1
285	Costs and complications associated with transvenous lead reoperation in cardiac implantable electronic devices. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 503-511.	1.7	3
286	Predictors of permanent pacemaker requirement after cardiac surgery for infective endocarditis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 329-334.	1.0	12
287	Characteristics of Blood Metabolic Profile in Coronary Heart Disease, Dilated Cardiomyopathy and Valvular Heart Disease Induced Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 622236.	2.4	11
288	The value of cardiac magnetic resonance imaging and programmed ventricular stimulation in patients with ventricular noncompaction and ventricular arrhythmias. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 745-754.	1.7	6
289	4D flow MRI left atrial kinetic energy in hypertrophic cardiomyopathy is associated with mitral regurgitation and left ventricular outflow tract obstruction. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2755-2765.	1.5	3

#	ARTICLE	IF	CITATIONS
290	Sudden Cardiac Death in Patients with Heart Disease and Preserved Systolic Function: Current Options for Risk Stratification. Journal of Clinical Medicine, 2021, 10, 1823.	2.4	12
291	Clinical review of sick sinus syndrome and atrial fibrillation. Herz, 2022, 47, 244-250.	1.1	8
292	2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: Executive summary. Indian Pacing and Electrophysiology Journal, 2021, 21, 349-366.	0.6	3
293	2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. JACC: Clinical Electrophysiology, 2021, 7, 1437-1472.	3.2	15
294	2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. Heart Rhythm, 2021, 18, 1888-1924.	0.7	56
295	2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. Indian Pacing and Electrophysiology Journal, 2021, 21, 367-393.	0.6	4
296	The mortality analysis of primary prevention patients receiving a cardiac resynchronization defibrillator (CRT-D) or implantable cardioverter-defibrillator (ICD) according to guideline indications in the improve SCA study. Journal of Cardiovascular Electrophysiology, 2021, 32, 2285-2294.	1.7	1
297	2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: executive summary. Cardiology in the Young, 2021, 31, 1717-1737.	0.8	4
298	2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients: Executive Summary. Heart Rhythm, 2021, 18, 1925-1950.	0.7	20
299	2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. Cardiology in the Young, 2021, 31, 1-104.	0.8	19
300	Long QT syndrome with potassium voltage-gated channel subfamily H member 2 gene mutation mimicking refractory epilepsy: case report. BMC Neurology, 2021, 21, 338.	1.8	5
301	PET Cardiac Imaging (Perfusion, Viability, Sarcoidosis, and Infection). Radiologic Clinics of North America, 2021, 59, 835-852.	1.8	8
303	Management of Heart Failure Patients with Reduced Ejection Fraction. , 2012, , 543-577.		12
304	Hypotension and Syncope. , 2012, , 885-895.		7
305	Pacing for Sinus Node Disease. , 2011, , 300-322.		2
306	Original Research: Deactivation of ICDs at the End of Life: A Systematic Review of Clinical Practices and Provider and Patient Attitudes. American Journal of Nursing, 2011, 111, 26-35.	0.4	86
307	Serum-Based Oxylipins Are Associated with Outcomes in Primary Prevention Implantable Cardioverter Defibrillator Patients. PLoS ONE, 2016, 11, e0157035.	2.5	10
308	Unicuspid Unicommissural Aortic Valve: An Extremely Rare Congenital Anomaly. Texas Heart Institute Journal, 2015, 42, 273-276.	0.3	27

#	ARTICLE	IF	CITATIONS
309	His Bundle Pacing: State of the Art. US Cardiology Review, 2018, 12, 57-65.	0.5	1
310	Lead Burden as a Factor for Higher Complication Rate in Patients With Implantable Cardiac Devices. Journal of Patient-centered Research and Reviews, 2015, 2, 17-24.	0.9	2
311	An unusual but reversible cause of ventricular fibrillation. Journal of the Royal College of Physicians of Edinburgh, The, 2013, 43, 119-121.	0.6	4
312	Sustained ventricular tachycardia in structural heart disease. Cardiology Journal, 2015, 22, 12-24.	1.2	8
314	Interesting presentation of a broad complex tachycardia during the head up tilt table test. BMJ Case Reports, 2021, 14, e245083.	0.5	1
315	Integrating State-of-the-Art Computational Modeling with Clinical Practice: The Promise of Numerical Methods. , 2010, , 1-19.		0
316	Diagnosis of Arrhythmias with Non-invasive Tools. , 2011, , 89-122.		0
317	Arrhythmias in Children. , 2011, , 355-392.		0
318	Cardiac Resynchronization Therapy in Adult Congenital Heart Disease. , 2011, , 138-146.		0
319	Clinical Trials of Atrial and Ventricular Pacing Modes. , 2011, , 234-256.		2
320	Bradycardia. , 0, , 204-211.		0
327	Medical Management of Arrhythmias and Conduction Disorders. , 2014, , 2999-3018.		0
328	Ventricular Arrhythmias in Congenital Heart Disease. , 2014, , 1009-1019.		0
330	Left Ventricular Non-Compaction: Current Controversy and New Insights. Journal of Genetic Syndromes & Gene Therapy, 2015, 06, .	0.2	1
331	Sudden Cardiac Death in the Young. , 2015, , 315-332.		0
332	Electrophysiology Updates in Adult Congenital Heart Disease. Texas Heart Institute Journal, 2016, 43, 409-411.	0.3	0
333	Neuromuscular Cardiomyopathies. , 2017, , 175-196.		0
334	CLINICAL AND ANGIOGRAPHIC PROFILE OF PATIENTS WITH COMPLETE HEART BLOCK. Journal of Evidence Based Medicine and Healthcare, 2017, 4, 2168-2170.	0.0	0

#	ARTICLE	IF	CITATIONS
335	Detection of biofilm-associated implant pathogens in cardiac device infections: High sensitivity of sonication fluid culture even in the presence of antimicrobials. <i>Journal of Global Infectious Diseases</i> , 2018, 10, 74.	0.5	5
337	A rare case of REM sleep-related bradyarrhythmia syndrome with concomitant severe hypertension: a case report and a review of literature. <i>Acta Medica Lituanica</i> , 2018, 25, 1-6.	0.3	7
338	Interdisciplinary stepwise approach for an effective and safe Mechanical Transvenous Lead Extraction. <i>Journal of Cardiovascular Medicine and Cardiology</i> , 0, , 059-063.	0.1	0
339	Etiology of Sudden Death. , 2021, , 17-35.		0
340	Implantable cardioverter defibrillators for sudden cardiac death prevention in China: A regional analysis from the improve SCA clinical trial. <i>International Journal of Heart Rhythm</i> , 2020, 5, 1.	0.0	0
341	Ventricular Tachycardia. , 2020, , 197-212.		0
342	A Patient with Cardiac Sarcoidosis in Whom an Abnormal Myocardial Uptake of Fluorine-18 Fluorodeoxyglucose and Sustained Ventricular Tachycardia Recurred 3.5 Years after Discontinuing Oral Corticosteroid Therapy. <i>Internal Medicine</i> , 2020, 59, 2275-2280.	0.7	0
343	Bradycardia-induced Torsade de Pointes - An arrhythmia Less Understood. <i>Indian Pacing and Electrophysiology Journal</i> , 2010, 10, 435-8.	0.6	7
344	Monitoring biventricular pacing parameters depending on the left ventricle lead configuration. <i>Experimental and Clinical Cardiology</i> , 2013, 18, 85-8.	1.3	2
345	Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity. <i>Texas Heart Institute Journal</i> , 2013, 40, 472-6.	0.3	14
346	Current Concepts of Premature Ventricular Contractions. <i>Journal of Lifestyle Medicine</i> , 2013, 3, 26-33.	0.8	17
347	Sarcoidosis Masquerading as Atrial Fibrillation: Interesting Case Discussion as Well as Recent Advances in Diagnosis and Management of Cardiac Sarcoidosis. <i>Journal of Atrial Fibrillation</i> , 2012, 5, 533.	0.5	2
348	Implantable cardioverter-defibrillator in a patient with dextrocardia situs inversus. <i>Caspian Journal of Internal Medicine</i> , 2016, 7, 294-296.	0.2	0
349	The subcutaneous implantable cardioverter defibrillator--review of the recent data. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 222-228.	0.2	5
350	The Diagnostic Challenges Associated with Type 2 Myocardial Infarction. <i>International Journal of Applied & Basic Medical Research</i> , 2021, 11, 131-138.	0.5	0
351	Distribution and prognostic impact of coronary artery disease and nonischemic cardiomyopathies in patients with electrical storm. <i>Coronary Artery Disease</i> , 2022, Publish Ahead of Print, .	0.7	0
352	Congenital atrioventricular heart block: From diagnosis to treatment. <i>Revista Portuguesa De Cardiologia</i> , 2022, 41, 231-240.	0.5	2
353	The diagnostic challenges associated with type 2 myocardial infarction. <i>International Journal of Applied & Basic Medical Research</i> , 2021, 11, 131.	0.5	3

#	ARTICLE	IF	CITATIONS
355	Electrocardiographic markers of cardiac resynchronization therapy response: delayed time to intrinsicoid deflection onset in lateral leads.. Journal of Geriatric Cardiology, 2022, 19, 21-30.	0.2	1
358	Differences in Treating Patients with Palpitations at the Primary Healthcare Level Using Telemedical Device Savvy before and during the COVID-19 Pandemic. Micromachines, 2022, 13, 1176.	2.9	1
359	2021 PACES expert consensus statement on the indications and management of cardiovascular implantable electronic devices in pediatric patients: Executive summary. Annals of Pediatric Cardiology, 2022, 15, 323.	0.5	1
360	HOT CRTâ€™The Effective Combination of Conventional Cardiac Resynchronization and His Bundle Pacing. Medicina (Lithuania), 2022, 58, 1828.	2.0	3
361	PET-CT in the diagnosis of cardiac and pulmonary sarcoidosis. Wiener Klinische Wochenschrift, 0, , .	1.9	0
362	Cardioverter-defibrillator reduces mortality risk in eligible ischemic and non-ischemic cardiomyopathy patients: Sub-analysis of the multi-center Improve SCA study. Indian Heart Journal, 2023, 75, 115-121.	0.5	1
363	Intermittent Chest Pain and Syncope in an 11-year-old Boy. Pediatrics in Review, 2023, 44, 176-181.	0.4	0
364	Complicated Pocket Infection in Patients Undergoing Lead Extraction: Characteristics and Outcomes. Journal of Clinical Medicine, 2023, 12, 4397.	2.4	0
365	Medical Management of Arrhythmias and Conduction Disorders. , 2023, , 1-21.		0
366	Do barrier dressings reduce cardiac implantable device infection: Protocol for a randomized controlled trial (BARRIER-PROTECT). Heliyon, 2023, 9, e22229.	3.2	0
367	Subcutaneous cardioverter-defibrillator implantation in an adult with congenital heart disease and left infra-mammary pacemaker. Indian Pacing and Electrophysiology Journal, 2023, , .	0.6	0